NALIRIF
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NALIRIF, covering 2025-09-19 to 2025-09-19. Get the full timeline:
Most recent: Clinical Trial Update: Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) [Phase 2]